Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp Purchases 15,000 Shares

Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp purchased 15,000 shares of the company’s stock in a transaction on Monday, February 24th. The stock was acquired at an average price of $0.92 per share, with a total value of $13,800.00. Following the purchase, the director now owns 176,141 shares of the company’s stock, valued at approximately $162,049.72. This represents a 9.31 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Clearside Biomedical Price Performance

Shares of CLSD opened at $0.88 on Tuesday. Clearside Biomedical, Inc. has a 1-year low of $0.80 and a 1-year high of $2.12. The stock has a market cap of $66.74 million, a PE ratio of -1.96 and a beta of 2.22. The firm has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.07.

Institutional Investors Weigh In On Clearside Biomedical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp lifted its position in Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after acquiring an additional 32,048 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock valued at $726,000 after buying an additional 32,672 shares during the last quarter. Investor s Fiduciary Advisor Network LLC purchased a new stake in shares of Clearside Biomedical in the fourth quarter valued at about $32,000. Finally, Johnson & Johnson purchased a new stake in shares of Clearside Biomedical in the third quarter valued at about $105,000. 18.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Wednesday, November 13th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Clearside Biomedical presently has an average rating of “Moderate Buy” and a consensus target price of $5.33.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.